{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:29:54Z","timestamp":1793255394848,"version":"4.5.0"},"reference-count":25,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Exogenous insulin antibody syndrome is a rare condition characterized by extreme insulin resistance caused by antibodies that neutralize the action of insulin. An 80-year-old woman with type 1 diabetes mellitus was transferred to an Australian quaternary hospital with refractory hyperglycemia and diabetic ketoacidosis despite receiving &amp;gt;300 units of insulin daily. Laboratory testing revealed a very high insulin antibody titer of 6758\u2005U\/mL (6758 kU\/L)(&amp;lt;0.4 U\/mL; &amp;lt;0.4\u2005kU\/L). Plasmapheresis was considered but was not pursued because of hemodynamic instability, multiple comorbidities and frailty. Treatment with high-dose methylprednisolone at 1\u2005mg\/kg for 5 days and 500\u2005mg of mycophenolate mofetil twice daily, followed by a tapering regimen of prednisone, resulted in a significant improvement in extreme insulin resistance. The total daily dose of insulin after treatment returned to a baseline of approximately 70 units and insulin antibody titers were reduced by 8-fold. Remission was maintained for more than 2 years until the patient died of an aggressive squamous cell carcinoma of the buccal mucosa.<\/jats:p>","DOI":"10.1210\/jcemcr\/luaf175","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T07:26:34Z","timestamp":1755847594000},"source":"Crossref","is-referenced-by-count":3,"title":["Exogenous Insulin Antibody Syndrome: A Rare Cause of Extreme Insulin Resistance Treated With High-dose Corticosteroids"],"prefix":"10.1210","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8096-8678","authenticated-orcid":false,"given":"Hari Haran","family":"Rajamohan","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Royal Brisbane and Women's Hospital , Brisbane, QLD 4006 ,","place":["Australia"]},{"name":"Royal Brisbane Clinical Unit, Faculty of Health, Medicine and Behavioural Sciences, University of Queensland , Brisbane, QLD 4006 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7012-4522","authenticated-orcid":false,"given":"Pierre-Nicolas","family":"Boyer","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Royal Brisbane and Women's Hospital , Brisbane, QLD 4006 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Royal Brisbane and Women's Hospital , Brisbane, QLD 4006 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lane","sequence":"additional","affiliation":[{"name":"Department of Immunology, Royal Brisbane and Women's Hospital , Brisbane, QLD 4006 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Love","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Royal Brisbane and Women's Hospital , Brisbane, QLD 4006 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"issue":"1","key":"2025082908270651900_luaf175-B1","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1530\/EC-17-0309","article-title":"Exogenous insulin antibody syndrome (EIAS): a clinical syndrome associated with insulin antibodies induced by exogenous insulin in diabetic patients","volume":"7","author":"Hu","year":"2018","journal-title":"Endocr Connect"},{"issue":"2","key":"2025082908270651900_luaf175-B2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1172\/JCI103262","article-title":"Insulin-I131 metabolism in human subjects: demonstration of insulin binding globulin in the circulation of insulin treated subjects","volume":"35","author":"Berson","year":"1956","journal-title":"J Clin Invest"},{"issue":"5","key":"2025082908270651900_luaf175-B3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4254\/wjh.v3.i5.99","article-title":"Insulin resistance and chronic liver disease","volume":"3","author":"Kawaguchi","year":"2011","journal-title":"World J Hepatol"},{"key":"2025082908270651900_luaf175-B4","doi-asserted-by":"crossref","first-page":"8390210","DOI":"10.1155\/2016\/8390210","article-title":"Glycated hemoglobin levels in patients with decompensated cirrhosis","volume":"2016","author":"Nadelson","year":"2016","journal-title":"Int J Endocrinol"},{"issue":"2","key":"2025082908270651900_luaf175-B5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0168-8227(03)00105-0","article-title":"Insulin lispro reduces insulin antibodies in a patient with type 2 diabetes with immunological insulin resistance","volume":"61","author":"Asai","year":"2003","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"2025082908270651900_luaf175-B6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.diabres.2010.06.025","article-title":"Clinical approach to the patient with diabetes mellitus and very high insulin requirements","volume":"90","author":"Ovalle","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"2025082908270651900_luaf175-B7","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1210\/jc.2004-2229","article-title":"Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial","volume":"90","author":"Fineberg","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025082908270651900_luaf175-B8","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1007\/s00125-010-1915-5","article-title":"Diabetes antibody standardization program: evaluation of assays for insulin autoantibodies","volume":"53","author":"Schlosser","year":"2010","journal-title":"Diabetologia"},{"issue":"1","key":"2025082908270651900_luaf175-B9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0091-6749(05)80122-8","article-title":"Resistance and allergy to recombinant human insulin","volume":"86","author":"Ganz","year":"1990","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2025082908270651900_luaf175-B10","first-page":"83","article-title":"Intractable diabetic ketoacidosis due to insulin antibody\u2013response to steroid therapy","volume":"45","author":"Chang","year":"1990","journal-title":"Zhonghua Yi Xue Za Zhi (Taipei)"},{"issue":"1","key":"2025082908270651900_luaf175-B11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0168-8227(93)90148-X","article-title":"Immunological resistance to human biosynthetic insulin\u2014effects of immunosuppression and plasmapheresis","volume":"19","author":"Mici\u0107","year":"1993","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"2025082908270651900_luaf175-B12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2337\/diacare.20.1.71","article-title":"Severe antibody-mediated human insulin resistance: successful treatment with the insulin analog lispro. a case report","volume":"20","author":"Lahtela","year":"1997","journal-title":"Diabetes Care"},{"issue":"2","key":"2025082908270651900_luaf175-B13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2169\/internalmedicine.39.143","article-title":"Antibody-mediated insulin resistance treated by cessation of insulin administration","volume":"39","author":"Hara","year":"2000","journal-title":"Intern Med"},{"issue":"3pt1","key":"2025082908270651900_luaf175-B14","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1399-5448.2008.00408.x","article-title":"Severe insulin resistance secondary to insulin antibodies: successful treatment with the immunosuppressant MMF","volume":"9","author":"Segal","year":"2008","journal-title":"Pediatr Diabetes"},{"issue":"1","key":"2025082908270651900_luaf175-B15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1464-5491.2008.02621.x","article-title":"Severe insulin resistance due to anti-insulin antibodies: response to plasma exchange and immunosuppressive therapy","volume":"26","author":"Greenfield","year":"2009","journal-title":"Diabet Med"},{"issue":"6","key":"2025082908270651900_luaf175-B16","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.2337\/dc11-0326","article-title":"Diabetic ketosis caused by the insulin analog aspart-induced anti-insulin antibody: successful treatment with the newest insulin analog glulisine","volume":"34","author":"Yanai","year":"2011","journal-title":"Diabetes Care"},{"issue":"1","key":"2025082908270651900_luaf175-B17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s41100-017-0096-9","article-title":"Poor glycemic control attributable to insulin antibody in a fulminant type 1 diabetes patient under hemodialysis: successful treatment with double filtration plasmapheresis and prednisolone","volume":"3","author":"Wada","year":"2017","journal-title":"Ren Replacement Ther"},{"issue":"2","key":"2025082908270651900_luaf175-B18","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.2337\/dc16-1975","article-title":"Extreme insulin resistance from insulin antibodies (not insulin receptor antibodies) successfully treated with combination immunosuppressive therapy","volume":"40","author":"Hao","year":"2017","journal-title":"Diabetes Care"},{"issue":"4","key":"2025082908270651900_luaf175-B19","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/jca.21905","article-title":"Exogenous insulin antibody syndrome treated with plasma exchange after an incomplete response to immunosuppressive therapy","volume":"36","author":"Zhuang","year":"2021","journal-title":"J Clin Apher"},{"issue":"3","key":"2025082908270651900_luaf175-B20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1089\/dia.2020.0438","article-title":"Recurrent diabetic ketoacidosis and extreme insulin resistance due to anti-insulin antibodies: response to immunosuppression and plasma exchange","volume":"23","author":"Ahmed","year":"2021","journal-title":"Diabetes Technol Ther"},{"issue":"10","key":"2025082908270651900_luaf175-B21","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1007\/s13300-021-01129-4","article-title":"Development of exogenous insulin antibody syndrome in a patient with newly diagnosed type 1 diabetes successfully treated with oral immunosuppressive monotherapy","volume":"12","author":"Jerkins","year":"2021","journal-title":"Diabetes Ther"},{"key":"2025082908270651900_luaf175-B22","first-page":"307","article-title":"Mycophenolate mofetil and plasmapheresis: a treatment option for severe insulin resistance caused by insulin antibodies","volume":"7","author":"Brooks","year":"2021","journal-title":"AACE Clin Case Rep"},{"issue":"3","key":"2025082908270651900_luaf175-B23","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2665-9913(21)00418-5","article-title":"Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients","volume":"4","author":"Boekel","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"2025082908270651900_luaf175-B24","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"2025082908270651900_luaf175-B25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00000441-200505000-00007","article-title":"Hypoglycemia and hyperglycemia due to insulin antibodies against therapeutic human insulin: treatment with double filtration plasmapheresis and prednisolone","volume":"329","author":"Koyama","year":"2005","journal-title":"Am J Med Sci"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/10\/luaf175\/64105821\/luaf175.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/10\/luaf175\/64105821\/luaf175.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T12:27:18Z","timestamp":1756470438000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luaf175\/8239565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,8,19]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luaf175","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,8,19]]},"article-number":"luaf175"}}